Biophore India Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.10 Cr
- Paid Up Capital ₹ 1.06 Cr
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 91.61 Cr
- Satisfied Charges ₹ 26.75 Cr
- Revenue Growth -6.69%
- Profit Growth 43.88%
- Ebitda 28.71%
- Net Worth 35.97%
- Total Assets 24.31%
About Biophore India Pharmaceuticals
Biophore India Pharmaceuticals Private Limited (BIPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 29 March 2007 and has a history of 17 years and ten months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.10 Cr and a paid-up capital of Rs 1.06 Cr.
The company currently has active open charges totaling ₹91.61 Cr. The company has closed loans amounting to ₹26.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Madhusudana Kothapalli, Jagadeesh Rangisetty, Manikreddy Pullagurla, and One other member serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24232TG2007PTC053381
- Company No.
053381
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Mar 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Biophore India Pharmaceuticals Private Limited offer?
Biophore India Pharmaceuticals Private Limited offers a wide range of products and services, including Turnkey Consultants & Solutions, Project Feasibility Studies, Nutraceuticals & Dietary Supplements, Dietary Supplements, Environment Protection & Auditing, Environment Protection Services, Building & Real Estate Developers, Construction Service.
Who are the key members and board of directors at Biophore India Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagadeesh Rangisetty  | Managing Director | 29-Mar-2007 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Madhusudana Kothapalli | Director | 15-Nov-2017 | Current |
| Manikreddy Pullagurla | Director | 22-Aug-2009 | Current |
Harcharan Singh  | Director | 10-Jul-2015 | Current |
Financial Performance of Biophore India Pharmaceuticals.
Biophore India Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.69% decrease. The company also saw a substantial improvement in profitability, with a 43.88% increase in profit. The company's net worth Soared by an impressive increase of 35.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biophore India Pharmaceuticals?
In 2023, Biophore India Pharmaceuticals had a promoter holding of 31.69% and a public holding of 68.31%. The company had 3 Subsidiaries and 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Glopec International (India) Private LimitedHarcharan Singh is a mutual person
Azico Biophore India Private LimitedJagadeesh Rangisetty and Manikreddy Pullagurla are mutual person
Leiutis Pharmaceuticals LlpMadhusudana Kothapalli, Jagadeesh Rangisetty and 2 more are mutual person
Zenara Pharma Private LimitedJagadeesh Rangisetty and Manikreddy Pullagurla are mutual person
- Alithia Pharmaceuticals Private Limited
Jagadeesh Rangisetty and Manikreddy Pullagurla are mutual person
Sionc Pharmaceuticals Private LimitedJagadeesh Rangisetty and Manikreddy Pullagurla are mutual person
Charges (Loans)
₹91.61 Cr
₹26.75 Cr
Charges Breakdown by Lending Institutions
- Others : 88.38 Cr
- Hdfc Bank Limited : 2.55 Cr
- Axis Bank Limited : 0.68 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Jul 2022 | Others | ₹27.00 Cr | Open |
| 31 Mar 2021 | Hdfc Bank Limited | ₹1.28 Cr | Open |
| 15 Feb 2021 | Hdfc Bank Limited | ₹1.28 Cr | Open |
| 23 Sep 2020 | Others | ₹5.74 Cr | Open |
| 26 Sep 2019 | Axis Bank Limited | ₹2.09 M | Open |
How Many Employees Work at Biophore India Pharmaceuticals?
Biophore India Pharmaceuticals has a workforce of 593 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biophore India Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biophore India Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
